胰高血糖素原，一种新型的生糖脂肪因子：在糖尿病治疗中的潜在意义。
Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus.
机构信息
Department of Physiology, Faculty of Medicine, Firat University, Elazig, Turkey.
Department of Biophysics, Faculty of Medicine, Firat University, Elazig, Turkey.
出版信息
Arch Physiol Biochem. 2023 Oct;129(5):1038-1044. doi: 10.1080/13813455.2021.1894178. Epub 2021 Mar 4.
OBJECTIVES
We aimed to investigate the effects of asprosin on diabetes with a focus on serum glucose, irisin, ghrelin, leptin levels and hepatic levels of triglycerides (TG), cholesterol, low-density lipoprotein (LDL).
METHODS
Asprosin (10 µg/kg) was administered intraperitoneally four times at 3-day intervals and then blood and hepatic parameters above mentioned were investigated in control and diabetic mice.
RESULTS
The administration of asprosin increased blood glucose level in healthy animals ( = .05) whereas it did not change blood glucose level in diabetic animals. In addition, while asprosin decreased irisin level and increased ghrelin level, it did not change leptin level in diabetic mice. Therewithal, asprosin decreased the increasing levels in hepatic TG, cholesterol, and LDL in diabetic mice.
CONCLUSIONS
Our novel findings implicate that asprosin may be a target molecule in preventing the development and complications of diabetes.
目的
本研究旨在探讨天冬酰胺酶对糖尿病的影响，重点关注血清葡萄糖、鸢尾素、胃饥饿素、瘦素水平以及肝组织甘油三酯（TG）、胆固醇、低密度脂蛋白（LDL）水平。
方法
天冬酰胺酶（10μg/kg）经腹腔注射，每 3 天给药 1 次，共给药 4 次，然后检测对照组和糖尿病小鼠上述血液和肝组织参数。
结果
天冬酰胺酶可升高健康动物的血糖水平（ = .05），但对糖尿病动物的血糖水平无影响。此外，天冬酰胺酶降低了糖尿病小鼠的鸢尾素水平，升高了胃饥饿素水平，但对瘦素水平无影响。同时，天冬酰胺酶可降低糖尿病小鼠肝组织 TG、胆固醇和 LDL 水平的升高。
结论
本研究的新发现提示天冬酰胺酶可能是预防糖尿病发生和并发症的靶标分子。
Zotero 插件